New ‘Guardian’ program to monitor post-market effectiveness through the Sentinel electronic data network will take five years to build, FDA’s Woodcock says.
FDA is planning to develop ways of using its Sentinel electronic data network to conduct post-market studies on drug effectiveness in addition to the safety surveillance it is already being used for, Center for Drug Evaluation and Research Director Janet Woodcock announced.
The planned drug effectiveness research program is being called Guardian, Woodcock told the eighth annual Sentinel public workshop Feb. 3....
Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.
New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.
The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.
